Activity of rhApo2L/TRAIL and rituximab against subcutaneous NHL xenografts. CB17 ICR SCID mice bearing established BJAB (A; n = 7 mice/group), DoHH-2 (B; n = 10 mice/group), Ramos RA1 (C; n = 9 mice/group), and SC-1 (D; n = 6 mice/group) tumors (approximately 200 mm³ in size) were treated with vehicle (black x), 60 mg/kg rhApo2L/TRAIL (open blue circle), 4 mg/kg rituximab (closed green triangle), or rhApo2L/TRAIL and rituximab (closed red square). rhApo2L/TRAIL was administered daily for 5 consecutive days followed by a 2-day break and a second 5-day treatment as indicated by the blue bar. Rituximab was administered once a week as indicated by the green arrow.